Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,421 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01132833 | Biomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving Chemotherapy | completed | — | 18 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 22, 2016 | clinicaltrials |
| NCT00891592 | Umbilical Cord Blood Transplant for Hematological Malignancies(UCB) | completed | Phase 1 | 5 | University of PennsylvaniaOTHER | 1 | Aug 19, 2016 |
| clinicaltrials |
| NCT01319422 | Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma | completed | Phase 2 | 40 | Yale UniversityOTHER | 1 | Aug 11, 2016 | clinicaltrials |
| NCT02861287 | Economic Evaluation of the Use of Plerixafor for Autologous HSC Transplantation for Multiple Myeloma(PLERIXAFOR) | completed | — | 60 | Institut Paoli-CalmettesOTHER | 1 | Aug 10, 2016 | clinicaltrials |
| NCT00560391 | Dasatinib in Combination With Revlimid (and Dexamethasone) | completed | Phase 1 | 35 | Bristol-Myers SquibbINDUSTRY | 3 | Aug 4, 2016 | clinicaltrials |
| NCT00133367 | Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus | completed | Phase 2 | 32 | Massachusetts General HospitalOTHER | 1 | Jul 25, 2016 | clinicaltrials |
| NCT02559583 | Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America(HOLA) | completed | — | 5,443 | Janssen-Cilag Ltd.INDUSTRY | 7 | Jul 20, 2016 | clinicaltrials |
| NCT00533923 | Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders | completed | Phase 2 | 25 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jul 18, 2016 | clinicaltrials |
| NCT02268890 | A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma | completed | Phase 4 | 18 | Johnson & Johnson Taiwan LtdINDUSTRY | 1 | Jul 11, 2016 | clinicaltrials |
| NCT01114282 | Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM | completed | Phase 1 | 11 | Stanford UniversityOTHER | 1 | Jul 6, 2016 | clinicaltrials |
| NCT00028600 | Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 2 | 60 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 4, 2016 | clinicaltrials |
| NCT00053196 | Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer | completed | Phase 2 | 82 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 1, 2016 | clinicaltrials |
| NCT00578942 | Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath | completed | Phase 2 | 48 | David Rizzieri, MDOTHER | 1 | Jun 24, 2016 | clinicaltrials |
| NCT00990717 | Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies | completed | Phase 1 | 8 | University Health Network, TorontoOTHER | 1 | Jun 23, 2016 | clinicaltrials |
| NCT00540644 | Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 70 | Attaya SuvannasankhaOTHER | 1 | Jun 21, 2016 | clinicaltrials |
| NCT00698776 | Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma | completed | Phase 1 | 6 | Yale UniversityOTHER | 1 | Jun 21, 2016 | clinicaltrials |
| NCT01241396 | A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure | completed | — | 2,396 | Janssen Pharmaceutica N.V., BelgiumINDUSTRY | 21 | Jun 20, 2016 | clinicaltrials |
| NCT00861250 | Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCT | completed | Phase 2 / Phase 3 | 47 | Tampere University HospitalOTHER | 1 | Jun 17, 2016 | clinicaltrials |
| NCT01079936 | Lenalidomide and High-Dose Melphalan | completed | Phase 1 / Phase 2 | 61 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 6, 2016 | clinicaltrials |
| NCT00410982 | Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies | completed | Phase 1 | 145 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 3, 2016 | clinicaltrials |
| NCT01286077 | Velcade Consolidation Bone Study | completed | Phase 2 | 106 | Janssen-Cilag International NVINDUSTRY | 8 | May 30, 2016 | clinicaltrials |
| NCT01034553 | Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 26 | Mayo ClinicOTHER | 1 | May 25, 2016 | clinicaltrials |
| NCT01376401 | Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 60 | PETHEMA FoundationOTHER | 1 | May 17, 2016 | clinicaltrials |
| NCT00299767 | Phase I Study of Sequential Cord Blood Transplants | completed | Phase 1 | 21 | Massachusetts General HospitalOTHER | 1 | May 11, 2016 | clinicaltrials |
| NCT00406978 | Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients(MPTD) | completed | Phase 1 / Phase 2 | 24 | Silvio AimeOTHER | 1 | May 10, 2016 | clinicaltrials |
| NCT00961467 | RMPT for Relapsed/Refractory Multiple Myeloma(RMPT) | completed | Phase 2 | 44 | Fondazione EMN Italy OnlusOTHER | 1 | May 10, 2016 | clinicaltrials |
| NCT01204164 | Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies(TG02-101) | completed | Phase 1 | 120 | Tragara Pharmaceuticals, Inc.INDUSTRY | 1 | May 6, 2016 | clinicaltrials |
| NCT01904175 | Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant | completed | — | 48 | Duke UniversityOTHER | 1 | May 5, 2016 | clinicaltrials |
| NCT01416246 | Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell Transplant | completed | N/A | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 29, 2016 | clinicaltrials |
| NCT00833833 | MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 259 | Celgene CorporationINDUSTRY | 2 | Apr 27, 2016 | clinicaltrials |
| NCT01394354 | Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)(VBDD) | completed | Phase 1 / Phase 2 | 34 | University Hospital FreiburgOTHER | 1 | Apr 6, 2016 | clinicaltrials |
| NCT00552396 | An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma | completed | Phase 1 | 32 | Innate PharmaINDUSTRY | 1 | Mar 31, 2016 | clinicaltrials |
| NCT01450215 | Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple Myeloma | completed | Phase 2 | 62 | Karolinska University HospitalOTHER | 1 | Mar 25, 2016 | clinicaltrials |
| NCT00999830 | Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma(REMYKIR) | completed | Phase 2 | 27 | Innate PharmaINDUSTRY | 1 | Mar 24, 2016 | clinicaltrials |
| NCT01359657 | Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 46 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 16, 2016 | clinicaltrials |
| NCT00618969 | Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors | completed | Phase 2 | 2 | University of ArizonaOTHER | 1 | Mar 3, 2016 | clinicaltrials |
| NCT00123773 | Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence | completed | Phase 2 | 1,075 | AHS Cancer Control AlbertaOTHER | 1 | Feb 26, 2016 | clinicaltrials |
| NCT00975975 | Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer | completed | Phase 2 | 17 | Indiana UniversityOTHER | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01352338 | Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)(REPEAT) | completed | Phase 1 / Phase 2 | 82 | UMC UtrechtOTHER | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01413568 | Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies | completed | Phase 1 / Phase 2 | 38 | Polyphor Ltd.INDUSTRY | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01530594 | Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma | completed | Phase 3 | 440 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT01094548 | Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy | completed | Phase 2 | 34 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Feb 22, 2016 | clinicaltrials |
| NCT00023530 | Blood and Marrow Transplant Clinical Research Network | completed | N/A | — | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Feb 18, 2016 | clinicaltrials |
| NCT00153933 | Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 58 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 25, 2016 | clinicaltrials |
| NCT01459653 | Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor(Monitor-GCSF) | completed | — | 1,496 | SandozINDUSTRY | 12 | Jan 11, 2016 | clinicaltrials |
| NCT00639054 | The Molecular Characterization of Multiple Myeloma at Relapse(MM-FISH/DNA) | completed | — | 134 | Rigshospitalet, DenmarkOTHER | 1 | Jan 7, 2016 | clinicaltrials |
| NCT01820546 | Cancer Stem Cells in Multiple Myeloma | completed | — | 96 | Ankara UniversityOTHER | 1 | Jan 6, 2016 | clinicaltrials |
| NCT00594126 | Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma | completed | Phase 1 | 20 | Geron CorporationINDUSTRY | 1 | Dec 24, 2015 | clinicaltrials |
| NCT00718601 | Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma | completed | Phase 1 | 40 | Geron CorporationINDUSTRY | 1 | Dec 24, 2015 | clinicaltrials |
Data updated 24 days agoSource updated Aug 22, 2016source: clinicaltrials